FLHLF
Filament Health Corp.·Healthcare
0.00
0.000%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.0052W H: $0.02
FLHLF NEWS
newsfilecorp.com
Mar 23
Red Light Holland Announces Filament Health Obtains Interim Order for Proposed Arrangement
Toronto, Ontario--(Newsfile Corp. - March 23, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that, further to the joint press release dated March 10, 2026, the Supreme Court of British Columbia issued an interim order (the "Interim Order") in connection with the previously announced acquisition by Red Light of all the issued and outstanding common shares of Filament (the "Filament Shares"), pursuant to a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia). Among other things, the Interim Order authorizes Filament to call, hold and conduct an annual general and special meeting (the "Meeting") of the holders of Filament Shares (the "Filament Shareholders") on April 24, 2026 at 8:00 a.m.
accessnewswire.com
Mar 16
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss management SAN FRANCISCO, CA / ACCESS Newswire / March 16, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Magdalena Biosciences ("Magdalena"), a US-based joint venture formed by Jaguar and Canada-based Filament Health Corp. (OTC:FLHLF) ("Filament"), has initiated a preclinical study evaluating the effectiveness of a whole leaf coca extract for appetite suppression. The coca leaf extract is Magdalena's drug candidate for post-GLP-1 weight loss management.
newsfilecorp.com
Mar 11
RETRANSMISSION: Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share transaction in which existing Red Light shareholders are expected to retain approximately 70% ownership following closing Transaction expected to streamline operations, consolidate teams, and improve capital efficiency Toronto, Ontario--(Newsfile Corp. - March 11, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that they have entered into a definitive arrangement agreement dated March 10, 2026 (the "Arrangement Agreement") pursuant to which Red Light will acquire Filament's business by way of a statutory plan of arrangement (the "Arrangement" or the "Transaction"). Key Transaction Highlights Adds GMP-compliant pharmaceutical manufacturing and Filament's Health Canada Level 8 Controlled Substances Dealer's Licence, strengthening Red Light's regulatory and production capabilities with Filament's Vancouver-based laboratory and manufacturing facility Integrates Filament's 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations Incorporates Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin supporting more than 70 academic and philanthropic research studies worldwide Combines Filament's Health Canada and FDA-authorized clinical development program and patented PEX010 botanical psilocybin drug candidate with Red Light's published microdosing protocol and real-world consumer data initiatives Leverages Red Light's experience in mass mushroom production, manufacturing coordination, scalability, packaging, logistics, and global brand development Positions the combined company to advance commercialization of patented microdosing psilocybin drug candidates, targeting jurisdictions with emerging regulatory pathways for clinical supply and distribution to authorized clinical research studies, compassionate use programs and other authorized uses Transaction expected to streamline operations, consolidate teams, and improve capital efficiency Strategic Rationale The Transaction brings together complementary intellectual property, regulatory licenses, research capabilities, and pharmaceutical manufacturing infrastructure to expand Red Light's platform focused on the development, production, and commercialization of natural psychedelic drug candidates.
newsfilecorp.com
Mar 10
Red Light Holland Signs Definitive Agreement with Filament Health to Expand Its Platform for Natural Psychedelic Drug Development and Microdosing Innovation
Expands Red Light's drug development platform with Filament's GMP manufacturing, Health Canada Dealer's Licence, Health Canada and FDA-authorized clinical programs, and 76 issued patents covering natural psilocybin manufacturing and formulation Combines Red Light's operational scale, global brand presence, and real-world microdosing data with Filament's pharmaceutical R&D capabilities and patented PEX010 botanical psilocybin drug candidate All-share transaction in which existing Red Light shareholders are expected to retain approximately 70% ownership following closing Transaction expected to streamline operations, consolidate teams, and improve capital efficiency Toronto, Ontario--(Newsfile Corp. - March 10, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light" or the "Company") and Filament Health Corp. (OTC: FLHLF) ("Filament") today announced that they have entered into a definitive arrangement agreement dated March 10, 2026 (the "Arrangement Agreement") pursuant to which Red Light will acquire Filament's business by way of a statutory plan of arrangement (the "Arrangement" or the "Transaction"). Key Transaction Highlights Adds GMP-compliant pharmaceutical manufacturing and Filament's Health Canada Level 8 Controlled Substances Dealer's Licence, strengthening Red Light's regulatory and production capabilities with Filament's Vancouver-based laboratory and manufacturing facility Integrates Filament's 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations Incorporates Filament's position as a leading supplier of pharmaceutical-grade natural psilocybin supporting more than 70 academic and philanthropic research studies worldwide Combines Filament's Health Canada and FDA-authorized clinical development program and patented PEX010 botanical psilocybin drug candidate with Red Light's published microdosing protocol and real-world consumer data initiatives Leverages Red Light's experience in mass mushroom production, manufacturing coordination, scalability, packaging, logistics, and global brand development Positions the combined company to advance commercialization of patented microdosing psilocybin drug candidates, targeting jurisdictions with emerging regulatory pathways for clinical supply and distribution to authorized clinical research studies, compassionate use programs and other authorized uses Transaction expected to streamline operations, consolidate teams, and improve capital efficiency Strategic Rationale The Transaction brings together complementary intellectual property, regulatory licenses, research capabilities, and pharmaceutical manufacturing infrastructure to expand Red Light's platform focused on the development, production, and commercialization of natural psychedelic drug candidates.
